Myasthenia gravis: monoclonal antihuman acetylcholine receptor antibodies used to analyze antibody specificities and responses to treatment.

摘要: We investigated the heterogeneity of serum antibodies to acetylcholine receptor (AChR) by competition with nine antihuman monoclonal in a cross-sectional study 36 patients myasthenia gravis (MG), and three who showed clinical improvement associated decrease total anti-AChR following immunologic treatment. Two specificities were more prevalent without thymoma, one these was cases beginning before age 40. Some stable during serial studies, whereas others fluctuated. found evidence groups antibody that had different control mechanisms may define regions receptor.